Calcitriol - CAS 32222-06-3
Catalog number: 32222-06-3
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Calcitriol is the hormonally active form of vitamin D.
RO215535, Topitriol
Canonical SMILES:
1.1,25-Dihydroxyvitamin D3 inhibits the proliferation of thyroid cancer stem-like cells via cell cycle arrest.
Peng W1, Wang K1, Zheng R1, Derwahl M1. Endocr Res. 2016 Mar 30:1-8. [Epub ahead of print]
BACKGROUND: An anti-proliferative effect of vitamin D has been reported in different carcinomas, including thyroid cancer. Cancer stem cells (CSCs), a very small fraction of cancer cells, are widely believed to be responsible for cancer initiation, relapse and metastasis.
2.Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
Kumar J1, Tran NG1, Schomberg J1, Streja E1, Kalantar-Zadeh K1, Pahl M2. J Ren Nutr. 2016 Mar 30. pii: S1051-2276(16)00045-5. doi: 10.1053/j.jrn.2016.02.006. [Epub ahead of print]
OBJECTIVE: The management of hyperparathyroidism in hemodialysis patients involves the administration of phosphate binders, vitamin D receptor activators, and calcimimetics. Intravenous paricalcitol has been preferred over oral calcitriol as it may cause less hypercalcemia and hyperphosphatemia. However, there is little data looking at the efficacy and tolerability of oral calcitriol in the calcimimetic era particularly in a real practice-based experience. The University of California, Irvine free-standing dialysis center converted from routine intravenous paricalcitol to oral calcitriol due to pharmacy purchasing preferences. We report the efficacy, safety, and cost of such a change.
3.Genetic Disorders Of Vitamin D Biosynthesis and Degradation.
Miller WL1. J Steroid Biochem Mol Biol. 2016 Apr 6. pii: S0960-0760(16)30097-8. doi: 10.1016/j.jsbmb.2016.04.001. [Epub ahead of print]
Vitamin D, an inactive secosteroid pro-hormone, is produced by the action of ultraviolet light on 7-dehydrocholesterol in the skin. The active hormone, 1,25(OH)2D is produced by sequential 25-hydroxylation in the liver, principally by CYP2R1, and 1α-hydroxylation in the kidney by CYP27B1. Mutations in CYP27B1 cause 1α-hydroxylase deficiency, also known as vitamin D dependent rickets type I or hereditary pseudo-vitamin D deficient rickets; very rare mutations in CYP2R1 can cause 25-hydroxylase deficienccy. Both deficiencies cause hypocalcemia, secondary hyperparathyroidism, severe rickets in infancy, and low serum concentrations of 1,25(OH)2D; both disorders respond to hormonal replacement therapy with calcitriol. The inactivation of vitamin D is principally initiated by its 23- and 24-hydroxylation by CYP24A1. Mutations in CYP24A1 can cause both severe neonatal hypercalcemia and a less severe adult hypercalcemic syndrome. Other pathways of vitamin D metabolism are under investigation, notably its 20-hydroxylation by the cholesterol side-chain cleavage enzyme, CYP11A1.
4.The Significance of Ultrasound in Determining Whether SHPT Patients Are Sensitive to Calcitriol Treatment.
Liang XX1, Li F2, Gao F2, Li CX2, Qiao XH2, Zhang JJ2, Du LF2. Biomed Res Int. 2016;2016:6193751. doi: 10.1155/2016/6193751. Epub 2016 Feb 29.
This study was to explore the significance of ultrasound in determining whether the patients with secondary hyperparathyroidism (SHPT) are sensitive to calcitriol treatment. According to the decrease value of parathyroid hormone (PTH), 42 SHPT patients were divided into two groups: drug susceptible group and drug insusceptible group. These 42 SHPT patients' ultrasound images were retrospectively analyzed. The morphology, size, number, blood flow, elastic modulus, and perfusion of the parathyroid glands were correlated with drug therapeutic outcome (oral calcitriol). Most SHPT patients with drug susceptible showed volume <438.50 mm(3) and number ≤2, with 0-1 structural and vascular patterns, associated with Relative Maximum Intensity (RIMAX) <1.59 and elastic modulus <18.8 kPa, whereas most SHPT patients with drug insusceptible showed volume ≥438.50 mm(3) and number ≥3, with 2-3 structural and vascular patterns, associated with Relative Maximum Intensity (RIMAX) ≥1.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related VD/VDR Products

CAS 50-14-6 Vitamin D2

Vitamin D2
(CAS: 50-14-6)

Vitamin D2 is a selective inhibitor of mammalian DNA polymerase A (pol A) with IC50 of 123 mM.

CAS 29261-12-9 25,26-Dihydroxyvitamin D3

25,26-Dihydroxyvitamin D3
(CAS: 29261-12-9)

Α hydroxylated metabolite of Vitamin D3

CAS 131918-61-1 Paricalcitol

(CAS: 131918-61-1)

Synthetic analog of vitamin D. Antihyperparathyroid.

CAS 112965-21-6 Calcipotriol

(CAS: 112965-21-6)

Calcipotriol, a 1,25-Dihydroxyvitamin D3 analogue, is used as topical treatment for psoriasis.

CAS 63283-36-3 Calcifediol monohydrate

Calcifediol monohydrate
(CAS: 63283-36-3)

Calcifediol monohydrate is a prehormone that is produced in the liver by hydroxylation of vitamin D3 (cholecalciferol) by the enzyme cholecalciferol 25-hydroxyl...

CAS 112875-61-3 Impurity of Calcipotriol

Impurity of Calcipotriol
(CAS: 112875-61-3)

Impurity of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.

CAS 147657-22-5 Calcipotriol monohydrate

Calcipotriol monohydrate
(CAS: 147657-22-5)

Calcipotriol increased hCAP18 mRNA expression in IL-17/IL-22-stimulated keratinocytes. However, LL37 peptide in the culture supernatants was reduced by calcipot...

CAS 131875-08-6 Lexacalcitol

(CAS: 131875-08-6)

KH1060 metabolism could be blocked by the cytochrome P450 inhibitor, ketoconazole. KH1060 was not an effective competitor of C24 oxidation of 1alpha,25-(OH)2D3....

Chemical Structure

CAS 32222-06-3 Calcitriol

Quick Inquiry

Verification code

Featured Items